ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses -Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th...

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses -Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th...

ObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress – virtual edition, December 2-5, 2020 Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve...